Pred-462 |best| Jun 2026
:
| Question | Current Knowledge | What Remains to Be Determined | |----------|-------------------|------------------------------| | | Patent and abstract hint at PI3Kδ/ER binding. | Confirmation via crystallography or proteomics. | | Biomarker Strategy | Preliminary work on phospho‑AKT levels. | Validation of predictive biomarkers (e.g., PIK3CA mutations). | | Resistance Mechanisms | In‑vitro selection of resistant clones shows upregulation of ABC transporters. | Clinical relevance of resistance pathways. | | Formulation | Cyclodextrin‑based oral suspension used in animal studies. | Final dosage form (tablet vs. solution) and bioavailability in humans. | | Regulatory Path | IND cleared in the U.S.; IND‑like submissions planned for EU/JP. | Timeline for NDA/MAA submission contingent on Phase II data. | PRED-462
For investors, clinicians, or researchers interested in the evolution of targeted breast‑cancer therapeutics, PRED‑462 warrants close monitoring as its Phase Ib/IIa data emerge over the next 12–24 months. : | Question | Current Knowledge | What
Leave a Reply